Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
115 participants
INTERVENTIONAL
2015-11-30
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pain Management of ACL Reconstruction
NCT03365908
Pain Relief Results After Anterior Cruciate Ligament (ACL) Reconstruction
NCT00022854
Pain Control for Anterior Cruciate Ligament Reconstruction Patients With Adductor Canal or Femoral Perineural Infusions
NCT03208478
Femoral Nerve Block Versus Adductor Canal Nerve Block for Peri-Operative Analgesia Following Anterior Cruciate Ligament (ACL) Reconstruction: Evaluation of Post-operative Pain and Strength
NCT03033589
Effectiveness of Continuous Femoral Nerve Block Versus Single Shot Femoral Nerve Block for Pain Control
NCT01916590
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The objective of this study is to compare the pain control benefit of two different types of nerve blocks. Ropivacaine, which is FDA-approved for use in both femoral nerve blocks as well as adductor canal blocks, will be utilized. The study will be comparing the efficacy between FDA approved treatments.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Femoral Nerve Block
Subjects undergoing anterior cruciate ligament (ACL) surgery will be randomized to receive 20 mL of ropivacaine 0.5% in the femoral nerve. Subjects will also receive standard of care Percocet 7.5/325 and naprosyn following surgery.
Ropivacaine 0.5%
Ropivacaine 0.5% will be administered to the femoral nerve or adductor canal.
Percocet 7.5/325
Percocet 7.5/325 will taken as needed up to every four hours.
Naprosyn 500 mg
Naprosyn 500 mg will be taken twice daily.
Adductor Canal Block
Subjects undergoing anterior cruciate ligament surgery will be randomized to receive 20 mL of ropivacaine 0.5% in the adductor canal. Subjects will also receive standard of care Percocet 7.5/325 and naprosyn following surgery.
Ropivacaine 0.5%
Ropivacaine 0.5% will be administered to the femoral nerve or adductor canal.
Percocet 7.5/325
Percocet 7.5/325 will taken as needed up to every four hours.
Naprosyn 500 mg
Naprosyn 500 mg will be taken twice daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ropivacaine 0.5%
Ropivacaine 0.5% will be administered to the femoral nerve or adductor canal.
Percocet 7.5/325
Percocet 7.5/325 will taken as needed up to every four hours.
Naprosyn 500 mg
Naprosyn 500 mg will be taken twice daily.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients willing and able to provide written informed consent
* Parents willing and able to provide written informed consent for minors
Exclusion Criteria
* Patients with liver dysfunction or renal failure
* Patients with a known allergy to ropivacaine
* Patients with a local infection
* Patients who take chronic pain medications
* Patients with an opioid tolerance
* Patients with known coagulopathy or bleeding risk.
* Patients who are getting neuraxial anesthesia for surgery
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Emory University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
John Xerogeanes
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Xerogeanes, MD
Role: PRINCIPAL_INVESTIGATOR
Emory University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Emory Healthcare Orthopaedics and Spine Center
Atlanta, Georgia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB00083740
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.